Englewood Lab
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Englewood Lab makes skincare and cosmetic products, moisturizers, face creams, sun-protection formulas, acne treatments, and color cosmetics, for beauty brands that want finished goods under their own labels.
Listed on KOSDAQ, South Korea's tech and small-cap exchange, it operates its manufacturing facilities in the United States, supplying cosmetics companies as a contract and private-label manufacturer. A notable structural feature is its specialization in over-the-counter drug-cosmetic products, such as sun-protection and acne formulas, which the U.S. Food and Drug Administration regulates as non-prescription medicines and which require additional safety and efficacy documentation.
Summary is AI-generated and may contain errors · figures from DART filings
Alongside product development, the company provides regulatory-compliance consulting to help clients navigate ingredient and import rules across different countries.
Englewood Lab in five facts
What does Englewood Lab do?
Englewood Lab makes skincare and cosmetic products, moisturizers, face creams, sun-protection formulas, acne treatments, and color cosmetics, for beauty brands that want finished goods under their own labels.
Where is Englewood Lab listed and in which sector?
Englewood Lab (Korean name: 잉글우드랩) trades under KRX code 950140 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Materials sector, Chemicals.
How large is Englewood Lab?
Its market capitalisation was US$110.7M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Englewood Lab's latest annual revenue and operating profit?
For fiscal year 2025, Englewood Lab reported revenue of US$115K, operating profit of US$19.8K and net income of US$13.2K, per its annual report on DART (data retrieved from DART on 2026-06-04). Revenue was up 14.1% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-06-04
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Operating results (consolidated) (preliminary) (fair disclosure)
Englewood Lab filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$36.6M (−9.7% year on year), operating profit of US$6.17M (−13.2% year on year) and net income of US$4.73M (+129.5% year on year).
Earnings · Aug 10 - Operating results (consolidated) (preliminary) (fair disclosure)
Englewood Lab filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$34.2M (+16.9% year on year), operating profit of US$3.85M (+22.5% year on year) and net income of US$4.86M (+117.7% year on year).
Earnings · May 8 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Englewood Lab reported consolidated results for FY2025: revenue of US$150M (+19% year on year), operating profit of US$25.8M (+98.8% year on year) and net income of US$17.1M (+26.4% year on year).
Earnings · Feb 20 - Operating results (consolidated) (preliminary) (fair disclosure)
Englewood Lab filed provisional (unaudited) consolidated results for Q4 2025: revenue of US$37.7M (+29.2% year on year), operating profit of US$6.42M (+150.8% year on year) and net income of US$5.18M (−4.6% year on year).
Earnings · Feb 20 - Cash/in-kind dividend decisionDividend · Jan 30